Скачать с ютуб Debate | Testosterone replacement in the aging male - Q&A в хорошем качестве

Debate | Testosterone replacement in the aging male - Q&A

Debate | Testosterone replacement in the aging male - Q&A Presented at: International Workshop on HIV & Aging 2016 Learn more about International Workshop on HIV & Aging 2021 that will take place from 23 September 2021 to 24 September 2021 via https://bit.ly/3tiGoJa The integration of antiretroviral therapy (ART) into HIV care has dramatically extended the life expectancy of those living with HIV. The longer life expectancy of people with HIV infection is changing the demographics of the HIV epidemic and currently, more than half of the people living with HIV are aged 45 or older. Recent estimates in Europe suggest that more than 70% of those with HIV will be over the age of 50 by 2030, with a greater burden of co-morbidities and associated treatments. In comparison to similar HIV-negative populations, HIV-positive persons, even when on effective ART, experience an excess of morbidity and mortality. Persons on ART rarely die from complications of AIDS, but instead have an early onset of aging complications including neurocognitive decline, osteoporosis and fractures, impaired physical function, frailty, and falls. The high priority of understanding the interaction between age and HIV infection is illustrated by recent summary reports from the HIV and Aging Consensus Project in the Journal of the American Geriatrics Society and ongoing NIH Program Announcements in “Multidisciplinary Studies of HIV/AIDS and Aging”, in addition to strong voices in the community. Registration for the webinar is open and fee is waived for healthcare professionals via this link https://bit.ly/2R1c2Of For the Enduring Materials of the 2016 edition visit https://bit.ly/3ttl6Zb For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/